{"id":533754,"date":"2021-09-02T08:04:20","date_gmt":"2021-09-02T12:04:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\/"},"modified":"2021-09-02T08:04:20","modified_gmt":"2021-09-02T12:04:20","slug":"kymera-therapeutics-to-present-at-upcoming-september-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\/","title":{"rendered":"Kymera Therapeutics to Present at Upcoming September Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WATERTOWN, Mass., Sept.  02, 2021  (GLOBE NEWSWIRE) &#8212; Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at two upcoming investor conferences:<\/p>\n<ul type=\"disc\">\n<li>Morgan Stanley 19th Annual Global Healthcare Conference: a fireside chat webcast will be available live on Thursday, September 9, 2021 at 1:15 p.m. ET.<\/li>\n<li>H.C. Wainwright 23rd Annual Global Investment Conference: an on demand webcast presentation will be available beginning on Monday, September 13, 2021 at 7:00 a.m. ET.<\/li>\n<\/ul>\n<p>Presentation webcasts will be available under &#8220;Events and Presentations&#8221; in the Investors section of the Company&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RiCuquJTiqdDCGynjYJVoy2J2bGT5Rx2VdtV4FtUW0O6ifS9prMvtJEWvgfDvXbmHg_tuRggeqyrdBICcq1vRg==\" rel=\"nofollow noopener\" target=\"_blank\">www.kymeratx.com<\/a>. Archived webcast replays will be available on the website for approximately 30 days.<\/p>\n<p>\n        <strong>About Kymera Therapeutics<\/strong><br \/>\n        <br \/>Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformative therapies while leading the evolution of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera\u2019s Pegasus\u2122 platform enables the discovery of novel small molecule degraders designed to harness the body\u2019s natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera\u2019s initial programs are IRAK4, IRAKIMiD, and STAT3, each of which addresses high impact targets within the IL-1R\/TLR or JAK\/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. Kymera\u2019s goal is to be a fully integrated biopharmaceutical company at the forefront of this new class of protein degrader medicines, with a pipeline of novel degrader medicines targeting disease-causing proteins that were previously intractable.<\/p>\n<p>Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a \u201cFierce 15\u201d biotechnology company by FierceBiotech and has been recognized by the Boston Business Journal as one of Boston\u2019s \u201cBest Places to Work.\u201d For more information about our people, science, and pipeline, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RiCuquJTiqdDCGynjYJVo0kqSozebH__lqK_pQBfxuP5YVg4UXHWVjNAMG4_3CG_rSoD4X0NuaHVW5YG0WfYVg==\" rel=\"nofollow noopener\" target=\"_blank\">www.kymeratx.com<\/a> or follow us on Twitter or LinkedIn.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Paul Cox<br \/>VP, Investor Relations and Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_I99udenbqEfgIqekkjQayyLkocUsq_sADG8JI4esvfjXSZlizvpQoc8g2pk9fjhL4XrScfguCnXh0Uv21lQlQ==\" rel=\"nofollow noopener\" target=\"_blank\">pcox@kymeratx.com<\/a><br \/>917-754-0207<\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Lissette L. Steele<br \/>Verge Scientific Communications for Kymera Therapeutics<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jIyKOObJ8XUyVIh8ue25BRZihrmbpcj_A_0nxf_QllVwbkKAKezyw0NZ3K9dPioefU7YkwbyvnB-L-kG3IFPEgEiEP7_Z6wyBZZ8r_C1l42FWrYroA-Mn_VFBM0DN4qY\" rel=\"nofollow noopener\" target=\"_blank\">lsteele@vergescientific.com<\/a><br \/>202-930-4762<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTA0MyM0Mzg1Njk5IzIyMDA4MzI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MTA1Y2Q2NTItMzAxOC00Y2JlLWEyOTMtM2RlZDQxOTY3ZDgyLTEyMTIzODU=\/tiny\/Kymera-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WATERTOWN, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at two upcoming investor conferences: Morgan Stanley 19th Annual Global Healthcare Conference: a fireside chat webcast will be available live on Thursday, September 9, 2021 at 1:15 p.m. ET. H.C. Wainwright 23rd Annual Global Investment Conference: an on demand webcast presentation will be available beginning on Monday, September 13, 2021 at 7:00 a.m. ET. Presentation webcasts will be available under &#8220;Events and Presentations&#8221; in the Investors section of the Company&#8217;s website at www.kymeratx.com. Archived webcast replays will be available on the website for approximately &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Kymera Therapeutics to Present at Upcoming September Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-533754","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kymera Therapeutics to Present at Upcoming September Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kymera Therapeutics to Present at Upcoming September Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at two upcoming investor conferences: Morgan Stanley 19th Annual Global Healthcare Conference: a fireside chat webcast will be available live on Thursday, September 9, 2021 at 1:15 p.m. ET. H.C. Wainwright 23rd Annual Global Investment Conference: an on demand webcast presentation will be available beginning on Monday, September 13, 2021 at 7:00 a.m. ET. Presentation webcasts will be available under &#8220;Events and Presentations&#8221; in the Investors section of the Company&#8217;s website at www.kymeratx.com. Archived webcast replays will be available on the website for approximately &hellip; Continue reading &quot;Kymera Therapeutics to Present at Upcoming September Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-02T12:04:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTA0MyM0Mzg1Njk5IzIyMDA4MzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kymera Therapeutics to Present at Upcoming September Investor Conferences\",\"datePublished\":\"2021-09-02T12:04:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\\\/\"},\"wordCount\":370,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTA0MyM0Mzg1Njk5IzIyMDA4MzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\\\/\",\"name\":\"Kymera Therapeutics to Present at Upcoming September Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTA0MyM0Mzg1Njk5IzIyMDA4MzI=\",\"datePublished\":\"2021-09-02T12:04:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTA0MyM0Mzg1Njk5IzIyMDA4MzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTA0MyM0Mzg1Njk5IzIyMDA4MzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kymera Therapeutics to Present at Upcoming September Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kymera Therapeutics to Present at Upcoming September Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Kymera Therapeutics to Present at Upcoming September Investor Conferences - Market Newsdesk","og_description":"WATERTOWN, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at two upcoming investor conferences: Morgan Stanley 19th Annual Global Healthcare Conference: a fireside chat webcast will be available live on Thursday, September 9, 2021 at 1:15 p.m. ET. H.C. Wainwright 23rd Annual Global Investment Conference: an on demand webcast presentation will be available beginning on Monday, September 13, 2021 at 7:00 a.m. ET. Presentation webcasts will be available under &#8220;Events and Presentations&#8221; in the Investors section of the Company&#8217;s website at www.kymeratx.com. Archived webcast replays will be available on the website for approximately &hellip; Continue reading \"Kymera Therapeutics to Present at Upcoming September Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-02T12:04:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTA0MyM0Mzg1Njk5IzIyMDA4MzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kymera Therapeutics to Present at Upcoming September Investor Conferences","datePublished":"2021-09-02T12:04:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\/"},"wordCount":370,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTA0MyM0Mzg1Njk5IzIyMDA4MzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\/","name":"Kymera Therapeutics to Present at Upcoming September Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTA0MyM0Mzg1Njk5IzIyMDA4MzI=","datePublished":"2021-09-02T12:04:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTA0MyM0Mzg1Njk5IzIyMDA4MzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTA0MyM0Mzg1Njk5IzIyMDA4MzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-present-at-upcoming-september-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kymera Therapeutics to Present at Upcoming September Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/533754","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=533754"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/533754\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=533754"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=533754"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=533754"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}